KYMR Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
65.0M
+89.1%
34.4M
+1097.4%
2.9M
+3.8%
2.8M
-75.9%
11.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
65.0M
+89.1%
34.4M
+1097.4%
2.9M
+3.8%
2.8M
-75.9%
11.5M
Operating Expenses
140.6M
+18.6%
118.6M
+17.7%
100.8M
+5.8%
95.3M
-0.8%
96.0M
R&D
119.5M
+21.7%
98.2M
+17.1%
83.8M
+13.1%
74.1M
-5.5%
78.4M
SG&A
21.1M
+3.8%
20.4M
+20.2%
16.9M
-2.3%
17.3M
-1.8%
17.6M
Operating Income
-75607000
+10.2%
-84215000
+14.0%
-97896000
-5.8%
-92521000
-9.4%
-84557000
EBITDA
-73577000
+10.5%
-82193000
+14.3%
-95864000
-10.8%
-86517000
-4.9%
-82473000
Net Income
-61211000
+11.6%
-69234000
+20.4%
-86981000
-5.8%
-82175000
-7.3%
-76614000
EPS (Basic)
$-0.62
+12.7%
$-0.71
+26.8%
$-0.97
-3.2%
$-0.94
+1.1%
$-0.95
EPS (Diluted)
$-0.62
+12.7%
$-0.71
+26.8%
$-0.97
-3.2%
$-0.94
+1.1%
$-0.95
Shares (Diluted)
98.2M
+0.7%
97.5M
+8.3%
90.1M
+3.2%
87.3M
+8.5%
80.4M
Kymera Therapeutics (KYMR) โ€” Financials